jueves, 18 de julio de 2019

Zika Virus Infection in Pregnant Women, Yucatan, Mexico - Volume 25, Number 8—August 2019 - Emerging Infectious Diseases journal - CDC

Zika Virus Infection in Pregnant Women, Yucatan, Mexico - Volume 25, Number 8—August 2019 - Emerging Infectious Diseases journal - CDC

Issue Cover for Volume 25, Number 8—August 2019

Volume 25, Number 8—August 2019
CME ACTIVITY - Synopsis

Zika Virus Infection in Pregnant Women, Yucatan, Mexico

On This Page
CME Introduction
Methods
Results
Discussion
CME Follow Up
Cite This Article
Figures
Figure
Tables
Table 1
Table 2
Table 3
Table 4
Table 5
Downloads
Article 
RIS [TXT - 2 KB] 
Article Metrics
Article has an altmetric score of 8
Metric Details
Related Articles
Cross-Protection against Congenital Zika Syndrome
Vertical Transmission of Zika Virus in Ae. aegypti
Prolonged Zika Virus RNA Detection in Semen of Immunosuppressed Patient
More articles on Zika
Yamila RomerComments to Author , Nina Valadez-Gonzalez, Silvina Contreras-Capetillo, Pablo Manrique-Saide, Gonzalo Vazquez-Prokopec, and Norma Pavia-Ruz
Author affiliations: Emory University, Atlanta, Georgia, USA (Y. Romer, G. Vazquez-Prokopec); Universidad Autónoma de Yucatan, Yucatan, Mexico (N. Valadez-Gonzalez, S. Contreras-Capetillo, P. Manrique-Saide, N. Pavia-Ruz)

Introduction

CME Logo
In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eidExternal Link; and (4) view/print certificate.
Release date: July 15, 2019; Expiration date: July 15, 2020

Learning Objectives

Upon completion of this activity, participants will be able to:
•     Describe the demographic and epidemiological findings of a prospective cohort of pregnant women during the initial phase of ZIKV introduction into Yucatán, Mexico
•     Explain the laboratory findings of a prospective cohort of pregnant women during the initial phase of ZIKV introduction into Yucatán, Mexico
•     Identify the clinical findings of a prospective cohort of pregnant women during the initial phase of ZIKV introduction into Yucatán, Mexico

CME Editor

Thomas J. Gryczan, MS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Authors

Disclosures: Yamila Romer, MD; Nina Valadez-González, DSc; Silvina Noemi Contreras-Capetillo, MS; Pablo Manrique-Saide, PhD; Gonzalo Vazquez-Prokopec, PhD; and Norma Pavia-Ruz, MS, have disclosed no relevant financial relationships.
Top

Abstract

We report demographic, epidemiologic, and clinical findings for a prospective cohort of pregnant women during the initial phase of Zika virus introduction into Yucatan, Mexico. We monitored 115 pregnant women for signs of active or recent Zika virus infection. The estimated cumulative incidence of Zika virus infection was 0.31 and the ratio of symptomatic to asymptomatic cases was 1.7 (range 1.3–4.0 depending on age group). Exanthema was the most sensitive clinical sign but also the least specific. Conjunctival hyperemia, joint edema, and exanthema were the combination of signs that had the highest specificity but low sensitivity. We did not find evidence of vertical transmission or fetal anomalies, likely because of the low number of pregnant women tested. We also did not find evidence of congenital disease. Our findings emphasize the limited predictive value of clinical features in areas where Zika virus cocirculates with other flaviviruses.
Zika virus, a mosquitoborne flavivirus, emerged abruptly in the Americas. It was first recognized in Brazil during 2015 in association with an outbreak of exanthematic disease, which was quickly linked to neurologic and immunological complications and congenital malformations (1–6). The first epidemic wave was centered in northeastern Brazil and associated with a high incidence of vertical transmission and cases of congenital disease that reached peaks of 49.9 cases/10,000 live births (7). The virus quickly spread to other countries and affected large sectors of Central America, South America, southern regions of North America, and the Caribbean (8). However, similarly high rates of congenital disease were not observed in other regions or in subsequent transmission waves in northeastern Brazil (9,10). The magnitude of the risk for vertical transmission and congenital syndromes, as well as possible associations that might increase or decrease these risks, remain unknown.
Multiple factors have been suggested to explain regional differences in disease incidence, including ethnic, environmental, nutritional, and virologic factors, as well as herd immunity (11–14). In addition, the possibility of overreporting of cases because of high public and epidemiologic awareness has been considered (11,15). The objectives of this study were to characterize the incidence, epidemiologic characteristics, clinical manifestations, and birth outcomes after Zika virus infection in pregnant women during the early phase of virus introduction in the state of Yucatan, Mexico.

Methods

Population
We have been evaluating integrated strategies to prevent Aedes mosquitoborne diseases in Yucatan State, Mexico. After health authorities confirmed the presence of Zika virus in Mexico, we designed a prospective study to quantify the incidence of disease and infection in pregnant women. The catchment area included a longitudinal cohort of 884 families (3,993 persons) residing in the cities of Merida, Ticul, and Progreso de Castro in Yucatan State (16). Merida and its metropolitan area, which have ≈1 million inhabitants, contain ≈50% of the Yucatan population. Progreso de Castro (population ≈37,400) and Ticul (population 32,000) are smaller urban areas. We enrolled consenting pregnant women from these areas during July 1, 2016–August 31, 2017. In addition, we independently enrolled pregnant women referred by physicians in primary care facilities or hospital facilities involved in our cohort study during the same period.
Clinical Follow-up of Pregnant Women and Newborns
Patient monitoring included a monthly visit for clinical assessment and sample collection (blood and urine), weekly doctor follow-up by text messages, and complete access to a telephone to report any clinical signs in pregnant women, their newborns, or any family contact. Fetal ultrasonography was performed at enrollment and every 3 months. At the first visit, a questionnaire was given to establish the clinical–epidemiologic profile. The pregnancy follow-up ended when the pregnancy was completed by delivery or fetal loss or the participant withdrew from the study. After initial clinical evaluation (anthropometric measurements, APGAR score [17], and clinical complications) and sample collection from the newborn, the postnatal follow-up included an evaluation during the first 18 months of life to detect development of any anomalies. These evaluations included cognitive and psychomotor status, neurology, ophthalmology, and genetic and audiology >1 time during this period. We used a definition of microcephaly based on the recommendation of the World Health Organization (18); cranial circumference >2 SDs below the mean for the age and sex of the baby.
Laboratory Testing
We detected Zika virus RNA by using real-time reverse transcription PCR (RT-PCR) for blood and urine samples as described (19–22). We also performed RT-PCR for Zika virus for blood of newborns and cerebrospinal fluid, as well as products of conception, including amniotic fluid, placenta, and fetal tissues, according to clinical needs (23). The RT-PCR studies were conducted in the Laboratory of Clinical Hematology of the Centro de Investigaciones Regionales (Merida, Mexico).
Statistical Analysis
We compared clinical and epidemiologic variables between pregnant women who were infected with Zika virus during pregnancy and women who remained Zika virus–negative by RT-PCR by calculating odds ratios and testing for their significance by using the Fisher 2-sided exact test. We evaluated differences in head circumference between groups of babies born to Zika virus–positive and –negative mothers by using the Wilcoxon signed rank test. Differences in p-values <0.05 were considered statistically significant. All analyses were performed by using SPSS version 24 software (IBM, https://www.ibm.comExternal Link).
Top

Results

A total of 115 pregnant women were included in the study: 66 from Merida, 45 from Ticul, and 4 from Progreso de Castro. One third were positive for Zika virus by RT-PCR of blood, urine, or both, at the initial evaluation (26 women) or during follow up (10 women). The cumulative incidence of Zika virus infection in the cohort was 0.31. The symptomatic to asymptomatic ratio among PCR-positive patients infected with Zika virus was 1.7 (range 1.3–4.0, depending on age group), and the highest proportion was in women 20–29 years of age (Table 1). Of the 26 positive patients at baseline, 22 had blood and urine samples, 3 had only blood samples, and 1 had only a urine sample. Of 22 paired blood and urine samples, 5 were Zika virus positive for both samples, 16 were Zika virus positive only for blood samples, and 1 was Zika virus positive only for a urine sample. Three unpaired blood samples and 1 unpaired urine sample were positive for Zika virus (Table 2).
In subsequent monthly testing, 11 (42%) blood samples remained positive and 2 urine samples that were negative in the first test became positive. In the third interval, 4 (15%) blood samples remained positive, and only 1 (3%) remained positive during the fourth interval. No urine sample was positive in 2 consecutive monthly controls. No intermittent urine virus shedding was detected. Seven (50%) of 14 women with virus shedding in urine had clinical symptoms at the time of virus detection. For 5 patients, the positive urine sample occurred at the same time as the positive blood sample, and for 2 patients, urine was positive after the blood sample showed a negative result. Of the 10 patients in whom infection developed during follow-up, 7 had paired blood–urine samples; 3 of those had positive blood and urine samples, 3 had only positive blood samples, and 1 had only a positive urine sample. Two patients were positive only for the urine sample, and 1 was positive only for the blood sample. For 1 patient, a urine sample negative at the time of detecting the infection became positive in the subsequent monthly control while the blood sample became negative. One patient had a blood sample that remained positive for >1 time interval.
Thumbnail of Distribution of cases of Zika virus infection, by epidemiologic week, Mexico, 2016–2017. A) Suspected and confirmed cases of Zika virus infection in Yucatan State and cases in Mexico. B) Cases of Zika virus infection among 115 pregnant women enrolled in study in 3 areas of Yucatan State.
Figure. Distribution of cases of Zika virus infection, by epidemiologic week, Mexico, 2016–2017. A) Suspected and confirmed cases of Zika virus infection in Yucatan State and cases in Mexico. B) Cases of...
We obtained the distribution of the cases per epidemiologic week for Yucatan State and the national epidemiologic curve (Figure, panel A). We detected cases of Zika virus infection 3 weeks before the passive surveillance system detected any cases, and time series of case counts in the cohort matched the epidemiologic curve for the passive surveillance system in shape and temporality (Figure, panel B). Of the Zika virus–positive mothers 8 were enrolled during the first trimester, 23 during the second trimester, and 5 during the third trimester. Of the Zika virus–negative mothers, 22 were enrolled during the first trimester, 39 during the second trimester, and 18 during the third trimester. Two weeks after the date of last menstruation was considered representative of the moment of conception and was established for 100 case-patients (33 positive for Zika virus and 67 negative for Zika virus).
If one considers the probability of acquiring Zika virus infection in relation to the moment of conception, those women who conceived during 2016 during epidemiologic weeks 13–40 had a statistically significant increased risk for acquiring the infection during pregnancy than for women who conceived during epidemiologic weeks 41–52 of 2016 and 1–12 of 2017 (odds ratio 5.86; p<0.001). For those patients who were positive at the time of enrollment, it was not possible to identify precisely when they became infected. In patients who were detected infected during follow-up, 0 became infected in the first trimester, 5 in the second trimester, and 5 in the third trimester. The average age of pregnant women in the study was 25 years, and we found no major differences in age distribution between Zika virus–positive and Zika virus–negative mothers (Table 3). We also found no difference in Zika virus infection for women of different socioeconomic status or between women residing in urban or rural areas (Table 3).
More than half (64%) of the women had >1 sign or symptom compatible with acute infection (Table 3). We found that headache, retro-orbital pain, arthralgia, conjunctival hyperemia, joint edema, exanthema, and pruritus, each had a strong association with Zika virus infection (Table 3). If we considered separately only those objective signs that showed a strong association (conjunctival hyperemia, joint edema, and exanthema), we found that 7 Zika virus–positive had all 3 signs and that none of the Zika virus–negative patients had these 3 signs. All Zika virus–positive patients who had joint edema also had exanthema and conjunctival hyperemia (Table 3). One Zika virus–negative patient had joint edema associated with exanthema but without conjunctival hyperemia.
A total of 17 Zika virus–positive patients had conjunctival injection, which was present in only 3 Zika virus–negative patients. For these 17 patients, this infection was associated with exanthema, and for 7 patients, this infection was associated with joint edema. Six patients had only exanthema. For subjective but unusual symptoms, such as retro-orbital pain (9 patients) and pruritus (11 patients), we observed that all but 1 patient with retro-orbital pain also had conjunctival hyperemia, and all had exanthema. Of patients with pruritus, all had exanthema, 10 had conjunctival hyperemia, and 6 had joint edema. The most frequent clinical findings among Zika virus–positive women were exanthema, arthralgia, and conjunctival hyperemia. Headache, retro-orbital pain, joint edema, and pruritus were the most specific signs and symptoms, but these symptoms had low sensitivity (Table 4). The proportion of symptomatic Zika virus–positive patients did not vary between cities. We did not observe hemorrhagic or systemic complications in any patient.
At the time of this study, all pregnancies were complete. Of these pregnancies, 3% were preterm, 2 for Zika virus–negative mothers and 1 for a Zika virus–positive mother (Table 5). Two fetal losses (2 in the first trimester and 1 in the third trimester) occurred among Zika virus–negative mothers. No newborns or products of conception were positive for Zika virus by virologic tests. We determined APGAR scores and percentiles of head circumference (Table 4). A Wilcoxon signed-rank test showed no significant difference between head circumference of babies from Zika virus–positive mothers and Zika virus–negative mothers (W = 213; p = 0.82). One newborn from a Zika virus–positive mother died during the first days of life because of gastroschisis. Other complications occurred among newborns but were nonspecific with regards to Zika virus infection status of the mothers (Table 4). Regarding the follow-up of the infants, although it is still in progress, no anomalies potentially related to Zika virus infection have been detected. Zika virus–positive mothers of 5 babies and Zika virus–negative mothers of 10 babies voluntarily withdrew from the study after delivery; this loss represented 13% of the cohort and was distributed proportionally between the 2 groups.
Top

Discussion

Yucatan State in Mexico, where 84% of the population resides in urban areas, has been a hotspot for Aedes mosquitoborne diseases for many decades. After introduction of Zika virus, routine measures to avoid vector propagation (e.g., ultra-low volume spraying indoors and outdoors in areas where symptomatic cases were reported, community education), as well as personal protection against mosquito bites, were implemented by the regional government. Such interventions failed to contain Zika virus propagation (24) and were not directed toward pregnant women. The detailed evaluation of a cohort of pregnant women who were positive for Zika virus shortly before conception or who became infected during their pregnancy provided no evidence of vertical transmission to the fetus or fetal malformations directly attributed to Zika virus. Nonetheless, our evaluation of this cohort documented useful symptomology and demographic trends of Zika virus infection in pregnant women in a poorly studied area to which dengue virus and other flaviviruses are endemic.
We showed by univariate analyses that the most sensitive clinical sign was exanthema, but it was also the least specific. Conjunctival hyperemia, joint edema, and exanthema was the combination with the highest level of specificity. Given the cocirculation of Zika virus with other arboviruses in the region with which it shares common clinical characteristics (exanthema, headache, arthralgia), it is expected that the specificity, positive predictive value, and diagnostic accuracy will decrease in relation to the differential diagnosis. The absence of fever, as well as the presence of exanthema, with or without other signs and symptoms, should alert the primary health system to suspect Zika virus infection in pregnant women at any time during the evolution of their pregnancy.
The proportion of symptomatic cases observed in our cohort can be an expression of the bias in our enrollment strategy because patients referred by physicians from primary care facilities are more likely to be positive for Zika virus infection and symptomatic. During the study period, active circulation of chikungunya virus and dengue virus was reported in the area. Because our samples were not tested for these virus infections, the chance of a co-infection cannot be ruled out. This finding represents a major limitation when we analyzed the clinical approach to orient diagnosis.
The risk for congenital disease among Zika virus–infected pregnant women has been estimated to be 1%–13% (25–28), and this rate increases when the maternal infection occurs during the first and second trimesters (29,30). Although we did not detect direct evidence of congenital transmission by testing with RT-PCR, development of abnormalities attributable to Zika virus infection could still occur during infancy (31). The low number of pregnant women enrolled in this study could have precluded detection of congenital infection. Alternately, the absence of overt congenital Zika virus infection in this small cohort could reflect the relative rarity of this condition, as observed in other countries (7,9,32,33). In addition, the limitations to implement serologic tests because cross-reactivity with other flavivirus (34–36) could have masked laboratory confirmation of Zika virus infection for patients after the waning of virus presence in fluids or tissues. The lack of clinical manifestations at birth does not eliminate the possibility of congenital disease, as reported (37,38).
There is recognized discordance in Zika virus detection on concurrent blood and urine samples (39–41). Urine samples are transiently positive after virus is detected in blood. Urine samples alone were insufficient in detecting 16 cases. A total of 43% of Zika virus–positive patients had a viremia for >4 weeks and 15% for >8 weeks. This prolonged viremia, which is unusual for other arboviruses, has been reported in pregnant women in other studies (42,43). The role of this prolonged viremia on pathogenesis of congenital diseases or dissemination of the infection is unclear.
Women who work outside had an increased risk for contracting the infection, potentially reflecting differential exposure to Aedes aegyptimosquitoes at locations other than their home (44,45); the highest incidence of pregnancies in women 20–29 years of age is consistent with results of another case series (32). We have not observed major differences in Zika virus infection in different age groups. We have observed that the highest proportion of Zika virus–positive women with symptomatic disease was among women 20–29 years of age, which is different from other studies that reported the highest ratio of symptomatic disease among women >30 years of age (46,47).
Although knowledge of clinical manifestations, natural history, and epidemiology of Zika virus in the Americas is incipient, the clinical–epidemiologic scenario involving severe congenital disease that was manifested initially in Brazil has not been observed at the same magnitude in other countries. Our prospective study of a cohort of pregnant women in Yucatan, Mexico, showed the value of active surveillance in early detection of infections and point to the limited predictive value of symptoms in areas where Zika virus cocirculates with other flaviviruses. In our study of 115 pregnant women with active or recent Zika virus infections, we found no evidence of congenital Zika virus disease.
Top
Dr. Romer is an infectious disease clinician and microbiologist in the Department of Environmental Sciences at Emory University, Atlanta, GA. Her primary research interests include arthropod-borne diseases.
Top

Acknowledgments

We thank Margarita Elsa Villarino for providing support and contributions to logistics for management and conclusion of this study.
This study was supported by the Yucatan Autonomous University and the Regional Research Center Hideyo Noguchi; the Mexico–United States Foundation for Science, Civil Association and Office of Infectious Disease; the Bureau for Global Health; and the US Agency for International Development under terms of an Interagency Agreement with the Centers for Disease Control and Prevention.
Top

References

  1. Cardoso  CW, Paploski  IA, Kikuti  M, Rodrigues  MS, Silva  MM, Campos  GS, et al. Outbreak of exanthematous illness associated with Zika, chikungunya, and dengue viruses, Salvador, Brazil. Emerg Infect Dis. 2015;21:2274–6. DOIExternal LinkPubMedExternal Link
  2. Zika virus outbreaks in the Americas. Wkly Epidemiol Rec. 2015;90:609–10.PubMedExternal Link
  3. Hennessey  M, Fischer  M, Staples  JE. Zika virus spreads to new areas—region of the Americas, May 2015–January 2016. MMWR Morb Mortal Wkly Rep. 2016;65:55–8. DOIExternal LinkPubMedExternal Link
  4. Pan American Health Organization/World Health Organization. Neurological syndrome, congenital malformations, and Zika virus infection. Implications for public health in the Americas. Epidemiological alert; 2015 [cited 2019 Apr 22]. https://www.paho.org/hq/dmdocuments/2015/2015-dec-1-cha-epi-alert-zika-neuro-syndrome.pdfExternal Link
  5. Miranda-Filho  DB, Martelli  CM, Ximenes  RA, Araújo  TV, Rocha  MA, Ramos  RC, et al. Initial description of the presumed congenital Zika syndrome. Am J Public Health. 2016;106:598–600. DOIExternal LinkPubMedExternal Link
  6. Smith  DW, Mackenzie  J. Zika virus and Guillain-Barré syndrome: another viral cause to add to the list. Lancet. 2016;387:1486–8. DOIExternal LinkPubMedExternal Link
  7. de Oliveira  WK, de França  GVA, Carmo  EH, Duncan  BB, de Souza Kuchenbecker  R, Schmidt  MI. Infection-related microcephaly after the 2015 and 2016 Zika virus outbreaks in Brazil: a surveillance-based analysis. Lancet. 2017;390:861–70. DOIExternal LinkPubMedExternal Link
  8. World Health Organization. WHO situation report. Zika virus, microcephaly, Gillain-Barre syndrome; December 1, 2016 [cited 2017 Aug 31]. http://www.who.int/emergencies/zika-virus/situation-reportExternal Link
  9. Cuevas  EL, Tong  VT, Rozo  N, Valencia  D, Pacheco  O, Gilboa  SM, et al. Preliminary report of microcephaly potentially associated with Zika virus infection during pregnancy—Colombia, January–November 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1409–13. DOIExternal LinkPubMedExternal Link
  10. World Health Organization. Emergencies: the history of Zika virus; 2016 [cited 2017 Aug 31]. http://www.who.int/emergencies/zika-virusExternal Link
  11. Butler  D. Brazil asks whether Zika acts alone to cause birth defects. Nature. 2016;535:475–6. DOIExternal LinkPubMedExternal Link
  12. Musso  D, Gubler  DJ. Zika Virus. Clin Microbiol Rev. 2016;29:487–524. DOIExternal LinkPubMedExternal Link
  13. Baud  D, Gubler  DJ, Schaub  B, Lanteri  MC, Musso  D. An update on Zika virus infection. Lancet. 2017;390:2099–109. DOIExternal LinkPubMedExternal Link
  14. Kuivanen  S, Korhonen  EM, Helisten  A-A, Huhtamo  E, Smura  T, Vapalahti  O. Differences in the growth properties of Zika virus foetal brain isolate and related epidemic strains in vitro. J Gen Virol. 2017;98:1744–8. DOIExternal LinkPubMedExternal Link
  15. Rodrigues  LC, Paixao  ES. Risk of Zika-related microcephaly: stable or variable? Lancet. 2017;390:824–6. DOIExternal LinkPubMedExternal Link
  16. Pavía-Ruz  N, Salha Villanueva , Granja  P, Balam-May  A, Longini  IM, Halloran  ME, et al.; Diana Patricia Rojas. Diana Patricia Rojas. Seroprevalence of dengue antibodies in three urban settings in Yucatan, Mexico. Am J Trop Med Hyg. 2018;98:1202–8. DOIExternal LinkPubMedExternal Link
  17. Casey  BM, McIntire  DD, Leveno  KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med. 2001;344:467–71. DOIExternal LinkPubMedExternal Link
  18. World Health Organization. Screening, assessment and management of neonates and infants with complications associated with Zika virus exposure in utero: rapid advice guideline. Geneva: The Organization; 2016.
  19. Lanciotti  RS, Kosoy  OL, Laven  JJ, Velez  JO, Lambert  AJ, Johnson  AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232–9. DOIExternal LinkPubMedExternal Link
  20. Bhatnagar  J, Rabeneck  DB, Martines  RB, Reagan-Steiner  S, Ermias  Y, Estetter  LB, et al. Zika virus RNA replication and persistence in brain and placental tissue. Emerg Infect Dis. 2017;23:405–14. DOIExternal LinkPubMedExternal Link
  21. Rabe  IB, Staples  JE, Villanueva  J, Hummel  KB, Johnson  JA, Rose  L, et al.; MTS. MTS. Interim guidance for interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep. 2016;65:543–6. DOIExternal LinkPubMedExternal Link
  22. Centers for Disease Control and Prevention. Revised diagnostic testing for Zika, chikungunya, and dengue viruses in US public health laboratories [cited 2017 August 31]. https://www.cdc.gov/zika/transmission/index.htlm
  23. Contreras-Capetillo  SN, Valadéz-González  N, Manrique-Saide  P, Carcaño-Castillo  RE, Pacheco-Tugores  F, Barrera-Pérez  HAM, et al.Birth defects associated with congenital Zika virus infection in Mexico. Clin Pediatr (Phila). 2018;57:927–36. DOIExternal LinkPubMedExternal Link
  24. Bisanzio  D, Dzul-Manzanilla  F, Gomez-Dantés  H, Pavia-Ruz  N, Hladish  TJ, Lenhart  A, et al. Spatio-temporal coherence of dengue, chikungunya and Zika outbreaks in Merida, Mexico. PLoS Negl Trop Dis. 2018;12:e0006298. DOIExternal LinkPubMedExternal Link
  25. Honein  MA, Dawson  AL, Petersen  EE, Jones  AM, Lee  EH, Yazdy  MM, et al.; US Zika Pregnancy Registry Collaboration. Birth defects among fetuses and infants of US women with evidence of possible Zika virus infection during pregnancy. JAMA. 2017;317:59–68. DOIExternal LinkPubMedExternal Link
  26. Duarte  G, Moron  AF, Timerman  A, Fernandes  CE, Mariani Neto  C, Almeida Filho  GL, et al. Zika virus infection in pregnant women and microcephaly. Rev Bras Ginecol Obstet. 2017;39:235–48. DOIExternal LinkPubMedExternal Link
  27. Rasmussen  SA, Jamieson  DJ, Honein  MA, Petersen  LR. Zika virus and birth defects: reviewing the evidence for causality. N Engl J Med. 2016;374:1981–7. DOIExternal LinkPubMedExternal Link
  28. Cauchemez  S, Besnard  M, Bompard  P, Dub  T, Guillemette-Artur  P, Eyrolle-Guignot  D, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016;387:2125–32. DOIExternal LinkPubMedExternal Link
  29. Noronha  L, Zanluca  C, Azevedo  MLV, Luz  KG, Santos  CN. Zika virus damages the human placental barrier and presents marked fetal neurotropism. Mem Inst Oswaldo Cruz. 2016;111:287–93. DOIExternal LinkPubMedExternal Link
  30. Singh  RK, Dhama  K, Malik  YS, Ramakrishnan  MA, Karthik  K, Tiwari  R, et al. Zika virus - emergence, evolution, pathology, diagnosis, and control: current global scenario and future perspectives - a comprehensive review. Vet Q. 2016;36:150–75. DOIExternal LinkPubMedExternal Link
  31. van der Linden  V, Pessoa  A, Dobyns  W, Barkovich  AJ, Júnior  HV, Filho  EL, et al. Description of 13 infants born during October 2015–January 2016 with congenital Zika virus infection without microcephaly at birth—Brazil. MMWR Morb Mortal Wkly Rep. 2016;65:1343–8. DOIExternal LinkPubMedExternal Link
  32. Brasil  P, Pereira  JP Jr, Moreira  ME, Ribeiro Nogueira  RM, Damasceno  L, Wakimoto  M, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016;375:2321–34. DOIExternal LinkPubMedExternal Link
  33. Coelho  AVC, Crovella  S. Microcephaly prevalence in infants born to Zika virus–infected women: a systematic review and meta-analysis.Int J Mol Sci. 2017;18:1714. DOIExternal LinkPubMedExternal Link
  34. Calisher  CH, Karabatsos  N, Dalrymple  JM, Shope  RE, Porterfield  JS, Westaway  EG, et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol. 1989;70:37–43. DOIExternal LinkPubMedExternal Link
  35. Allwinn  R, Doerr  HW, Emmerich  P, Schmitz  H, Preiser  W. Cross-reactivity in flavivirus serology: new implications of an old finding?Med Microbiol Immunol (Berl). 2002;190:199–202. DOIExternal LinkPubMedExternal Link
  36. Mansfield  KL, Horton  DL, Johnson  N, Li  L, Barrett  AD, Smith  DJ, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92:2821–9. DOIExternal LinkPubMedExternal Link
  37. Aragao  MFVV, Holanda  AC, Brainer-Lima  AM, Petribu  NCL, Castillo  M, van der Linden  V, et al. Nonmicrocephalic infants with congenital Zika syndrome suspected only after neuroimaging evaluation compared with those with microcephaly at birth and postnatally: how large is the Zika virus “iceberg”? AJNR Am J Neuroradiol. 2017;38:1427–34. DOIExternal LinkPubMedExternal Link
  38. de Fatima Vasco Aragao  M, van der Linden  V, Brainer-Lima  AM, Coeli  RR, Rocha  MA, Sobral da Silva  P, et al. Clinical features and neuroimaging (CT and MRI) findings in presumed Zika virus related congenital infection and microcephaly: retrospective case series study. BMJ. 2016;353:i1901. DOIExternal LinkPubMedExternal Link
  39. Sakkas  H, Economou  V, Papadopoulou  C. Zika virus infection: Past and present of another emerging vector-borne disease. J Vector Borne Dis. 2016;53:305–11.PubMedExternal Link
  40. Kutsuna  S, Kato  Y, Takasaki  T, Moi  M, Kotaki  A, Uemura  H, et al. Two cases of Zika fever imported from French Polynesia to Japan, December 2013 to January 2014 [corrected]. [corrected]. Euro Surveill. 2014;19:20683. DOIExternal LinkPubMedExternal Link
  41. Paz-Bailey  G, Rosenberg  ES, Doyle  K, Munoz-Jordan  J, Santiago  GA, Klein  L, et al. Persistence of Zika virus in body fluids: final report.N Engl J Med. 2017;379:1234–43. DOIExternal LinkPubMedExternal Link
  42. Driggers  RW, Ho  C-Y, Korhonen  EM, Kuivanen  S, Jääskeläinen  AJ, Smura  T, et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Engl J Med. 2016;374:2142–51. DOIExternal LinkPubMedExternal Link
  43. Meaney-Delman  D, Oduyebo  T, Polen  KN, White  JL, Bingham  AM, Slavinski  SA, et al.; U.S. Zika Pregnancy Registry Prolonged Viremia Working Group. Prolonged detection of Zika virus RNA in pregnant women. Obstet Gynecol. 2016;128:724–30. DOIExternal LinkPubMedExternal Link
  44. Stoddard  ST, Forshey  BM, Morrison  AC, Paz-Soldan  VA, Vazquez-Prokopec  GM, Astete  H, et al. House-to-house human movement drives dengue virus transmission. Proc Natl Acad Sci U S A. 2013;110:994–9. DOIExternal LinkPubMedExternal Link
  45. Vazquez-Prokopec  GM, Montgomery  BL, Horne  P, Clennon  JA, Ritchie  SA. Combining contact tracing with targeted indoor residual spraying significantly reduces dengue transmission. Sci Adv. 2017;3:e1602024. DOIExternal LinkPubMedExternal Link
  46. Duffy  MR, Chen  T-H, Hancock  WT, Powers  AM, Kool  JL, Lanciotti  RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–43. DOIExternal LinkPubMedExternal Link
  47. Flamand  C, Fritzell  C, Matheus  S, Dueymes  M, Carles  G, Favre  A, et al. The proportion of asymptomatic infections and spectrum of disease among pregnant women infected by Zika virus: systematic monitoring in French Guiana, 2016. Euro Surveill. 2017;22:22. DOIExternal LinkPubMedExternal Link
Top
Figure
Tables
Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to http://www.medscape.org/journal/eidExternal Link. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.
You must be a registered user on http://www.medscape.orgExternal Link. If you are not registered on http://www.medscape.orgExternal Link, please click on the “Register” link on the right hand side of the website.
Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.netExternal Link. For technical assistance, contact CME@medscape.netExternal Link. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.orgExternal Link. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.
Article Title:
Zika Virus Infection in Pregnant Women, Yucatan, Mexico

CME Questions

1.   Your patient is a 26-year-old pregnant woman in Merida, Yucatán, Mexico, who may have been exposed to Zika virus (ZIKV) infection during her second trimester. According to the prospective cohort study by Romer and colleagues, which of the following statements about demographic and epidemiological findings of pregnant women during the initial phase of ZIKV introduction into Yucatán, Mexico, is correct?
A. Among 115 pregnant women monitored for signs of active or recent ZIKV infection, estimated ZIKV cumulative incidence was 0.12 and symptomatic-to-asymptomatic ratio was 3.2
B. Risk for ZIKV infection was consistent throughout 2016 and 2017
C. Older age, socioeconomic status, and rural vs urban residence predicted ZIKV positivity
D. The cohort detected ZIKV cases 3 weeks before Yucatán State’s passive surveillance system, but shape and temporality of the epidemiologic curve was similar in both
2.   According to the prospective cohort study by Romer and colleagues, which of the following statements about the laboratory findings of pregnant women with recent or acute ZIKV infection during the initial phase of ZIKV introduction into Yucatán, Mexico, is correct?
A. There is known to be high concordance in ZIKV detection from concurrent blood and urine samples
B. Prolonged viremia in this study and others is unusual for other arboviruses, and its role in pathogenesis of congenital diseases or on dissemination of infection is unclear
C. Of 22 paired blood and urine samples at baseline, 10 were positive for ZIKV infection in both samples
D. Urine samples alone were sufficient to detect nearly all cases
3.   According to the prospective cohort study by Romer and colleagues, which of the following statements about clinical findings of pregnant women with recent or acute ZIKV infection during the initial phase of ZIKV introduction into Yucatán, Mexico, is correct?
A. Exanthema was the most specific clinical sign, and clinical features were highly predictive of ZIKV infection
B. The combination of signs with highest specificity was fever, retro-orbital pain, and joint edema, but sensitivity was low
C. Congenital ZIKV disease was detected in 3 newborns
D. Physicians should suspect ZIKV infection in pregnant women with exanthema and without fever, with or without other signs and symptoms
Top
Cite This Article

DOI: 10.3201/eid2508.180915
Original Publication Date: 7/15/2019
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)